Skip to content
10-Q

Quarterly Report

Alto Neuroscience, Inc. ANRO

0001999480-26-000012

← back to feed
Filed
May 13, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 8, 2026 35.09M sh
Shares Diluted Q1 2026 · Mar 31, 2026 32.89M sh
Shares Diluted Q1 2026 · Mar 31, 2025 27.05M sh
Capex Q1 2026 · Mar 31, 2026 $556K
Capex Q1 2026 · Mar 31, 2025 $24K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$27.09M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$16.56M
Long Term Debt Q1 2026 · Mar 31, 2026 $13.89M
Long Term Debt Q1 2026 · Dec 31, 2025 $16.17M
Short Term Debt Q1 2026 · Mar 31, 2026 $2.14M
Short Term Debt Q1 2026 · Dec 31, 2025 $585K
Cash And Equivalents Q1 2026 · Mar 31, 2026 $263.76M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $176.48M
Stockholders Equity Q1 2026 · Mar 31, 2026 $243.37M
Stockholders Equity Q1 2026 · Dec 31, 2025 $151.14M
Stockholders Equity Q1 2026 · Mar 31, 2025 $139.1M
Stockholders Equity Q1 2026 · Dec 31, 2024 $151.46M
Current Liabilities Q1 2026 · Mar 31, 2026 $13.12M
Current Liabilities Q1 2026 · Dec 31, 2025 $11.33M
Total Liabilities Q1 2026 · Mar 31, 2026 $32.89M
Total Liabilities Q1 2026 · Dec 31, 2025 $33.55M
Current Assets Q1 2026 · Mar 31, 2026 $269.13M
Current Assets Q1 2026 · Dec 31, 2025 $177.72M
Total Assets Q1 2026 · Mar 31, 2026 $276.26M
Total Assets Q1 2026 · Dec 31, 2025 $184.69M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.80
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.56
Eps Basic Q1 2026 · Mar 31, 2026 −$0.80
Eps Basic Q1 2026 · Mar 31, 2025 −$0.56
Sga Expense Q1 2026 · Mar 31, 2026 $6.84M
Sga Expense Q1 2026 · Mar 31, 2025 $5.7M
Rd Expense Q1 2026 · Mar 31, 2026 $20.29M
Rd Expense Q1 2026 · Mar 31, 2025 $9.97M
Net Income Q1 2026 · Mar 31, 2026 −$26.24M
Net Income Q1 2026 · Mar 31, 2025 −$15.17M
Operating Income Q1 2026 · Mar 31, 2026 −$27.14M
Operating Income Q1 2026 · Mar 31, 2025 −$15.68M